New ASH guidelines outline optimal management for a subgroup of patients with leukemia that historically has been challenging to treat.Two papers published simultaneously in Blood Advances address ...

Cancer researchers including senior author Christopher Hourigan (at left) and first author Rasha Al-Ali of Virginia Tech’s Fralin Biomedical Research Institute found that a highly sensitive DNA-based ...

Acute myeloid leukemia, or AML, is a rare and aggressive cancer that can affect people of all ages. Kiran Vanaja, an ...

Structural nanomedicine — what helped give us the COVID vaccine — may now be the key to a potent blood cancer treatment that’s had remarkable early results.

Agios Pharma’s Tibsovo gets US FDA nod to treat relapsed/refractory acute myeloid leukemia: Cambridge Tuesday, July 24, 2018, 17:00 Hrs [IST] Agios Pharmaceuticals, Inc, a leade ...

Total revenue of $68.7 million in 4Q25 and $172.4 million in FY2025 – – Revuforj® (revumenib) net revenue of $44.2 million in 4Q25, a 38% increase vs 3Q25, and $124.8 million in FY2025 – – Niktimvo™ ...

New research into acute myeloid leukemia could change future treatment approaches.

Blackstone Life Sciences ("BXLS") today announced a research and development funding agreement to advance the clinical ...

WVU Cancer Institute became the first in the world to treat ultra-rare, aggressive CD19-positive MPAL with subcutaneous blinatumomab in a Phase II trial.

(Beyond Pesticides. February 24, 2026) Leukemia is the leading contributor to the clear rise in childhood cancer cases over the last few decades, and the general association of pesticide exposures ...